Background: Few genes have germline mutations which predispose men to more aggressive prostate cancer (PCa). This study evaluated the contribution of germline loss of function (LOF) variants in PPFIBP2 to risk of lethal PCa.
| INTRODUCTION
Prostate cancer (PCa) is the second most common cancer in men and the fifth leading cause of death throughout the world, with an estimated 1 111 700 new cases and 307 500 deaths every year. 1 The wide discrepancy between these latter two numbers emphasizes the wide spectrum of clinical behavior of PCa, with many if not most cancers diagnosed being indolent. The development of prognostic markers capable of distinguishing risk for aggressive or lethal PCa versus indolent cases is critical to more effective risk assessment, early detection, and timely clinical intervention.
Estimated to be one of the most heritable cancers, 42-57% of the inter-individual variation in PCa risk has been attributed to genetic factors. 2, 3 It is well established that genetic risk factors for PCa include low-penetrance common variants (risk allele frequencies >1%) in noncoding regions, as well as moderate-to high-penetrance rare variants (risk allele frequencies <1%) in coding regions. Over 100 common germline variants associated with PCa risk have been identified thus far, explaining ∼33% of familial risk. 4 However, these common variants are quite limited in differentiating risk of lethal PCa from low-risk cases. 5, 6 Currently, there is accumulating evidence that rare mutations in a small number of moderate to high-penetrance genes, particularly BRCA2, and possibly BRCA1, HOXB13, and ATM, can increase general PCa risk as well as the likelihood of more aggressive or lethal disease. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Since rare germline variants in moderate-to highpenetrance genes are potentially clinically actionable, efforts to identify novel genes with reliable prognostic value are of particular relevance. Whole-exome sequencing of large PCa cohorts can generate candidate genes for these discovery efforts.
A recent genome-wide association study (GWAS) 
| Statistical analysis
The clinicopathologic characteristics including age and serum PSA value at the time of diagnosis were compared between lethal and lowrisk cases using a Mann-Whitney U-test. Consortium (ExAC-NFE) using a two-sided binominal test. Logistic regression analysis was used to evaluate the odds ratio (OR) of carrying PPFIBP2 mutation after adjusting for age and genetic background.
Genetic background was estimated based on information from the 3234 non-PCa related SNPs in the genome that are common in the lethal and indolent PCa cases. 27 Time to death between mutation carriers and non-carriers in lethal cases was compared using KaplanMeier survival and Cox regression analysis. In the survival analysis,
ATM and BRCA1/2 mutation carriers in the lethal cohort were excluded from analysis since there is evidence of decreased survivability for these three gene carriers. 18 A P-value of less than 0.05 (two-sided) was 
| RESULTS
Lethal PCa patients (n = 516) and PCa patients with low-risk disease (n = 898) were included in this study ( Table 1) . The majority of patients were European American (1272 out of 1414, 90.0%). The remaining study subjects consisted of 101 African American cases and 41 cases reporting other ancestries. The lethal PCa cohort had a younger median age at diagnosis, a higher median PSA level, and a larger proportion of patients with Gleason score ≥7 than low-risk cases (all P-values < 0.05).
The PPFIBP2 germline pathogenic and likely pathogenic mutations detected in the study subjects are described in Figure 1 and frequencies of the mutations in different cohorts is provided in Table 2 .
A higher overall carrier frequency was observed in lethal cases (7 or 1.36%) than in low-risk cases (1 or 0.11%), P = 0.0046. PPFIBP2 mutation carriers were only observed in European American patients, slightly increasing the carrier rate in this population to 1.52% in lethal PCa patients and 0.12% in low-risk PCa patients P = 0.0029. The estimated OR of PPFIBP2 mutation status for lethal PCa risk in European American population was 13.8 (95%CI: 1.76-620.7). After adjusting for age at diagnosis and first two eigens of patients' genetic background, this estimate remained significant (OR = 14.6, 95% confidence interval:
2.4-284.9, P = 0.015).
Among the eight mutations observed, only three were also detected in non-Finnish European individuals from the ExAC database (ExAC-NFE) where they were observed with low frequencies (0.003-0.02%). We calculated the overall frequency of PPFIBP2 ). Moreover, we examined the germline WES data from 498 clinically localized PCa cases in TCGA, 28 and no PPFIBP2 carriers were observed. Thus, the PPFIBP2 mutation frequency was elevated in our lethal PCa cohort compared to patients with localized PCa in the TCGA cohort, P = 0.0058.
The characteristics of PPFIBP2 mutation carriers and non-carriers in European American population are described in Table 3 . The detailed information on characteristics of mutation carriers is provided in Supplementary Table S1 . The PPFIBP2 carriers had a higher median PSA at diagnosis compared to non-carriers (9.1 ng/mL vs 5.2 ng/mL, FIGURE 1 Lollipop plot of germline pathogenic and likely pathogenic mutations in PPFIBP2. Complementary DNA position and amino acid change of each mutation are presented in the plot P = 0.017), and they were also more likely to have high risk disease (Gleason score ≥8) compared to non-carriers (62.5% vs 12.7%, P = 0.0007). The carriers were younger at diagnosis (61.5 vs 65.0) and had a shorter survival time after diagnosis (5.0 years vs 8.0 years), although the difference was not significant (P > 0.05). In a multivariable logistic regression analysis adjusting for age, PSA at diagnosis and genetic background (Table 4) , carrying a PPFIBP2 mutation was marginally associated with increased risk for lethal PCa (OR = 13.9, P = 0.051). When the lethal cohort was stratified by age at death, the mutation carrier frequency in patients dying under age of 70 was 2.26% versus 0.29% in patients dying at a later age, (P = 0.0054). In the multivariable analysis, carrying a PPFIBP2 mutation was associated with early death (under age of 70) (OR = 52.53, P = 0.018) (Supplementary Table S2 ).
In the survival analysis of time to PCa-specific death after diagnosis among 436 European American lethal cases, PPFIBP2 mutation carriers were significantly associated with shorter survival when compared with non-carriers after adjusting for age at diagnosis, 
| DISCUSSION
In an exome wide search for genes with sequence variants associated with the lethal phenotype of PCa, we identified PPFIBP2, a gene 
1.92E-05
The cDNA positions were annotated referring to PPFIBP2 Transcript NM_003621. Using Fisher's exact for frequency comparison. *OR and P-value adjusted for age and the first 2 eigens of genetic background using logistic regression. **P-value was calculated by two-sided Binominal test.
implicated from previous GWAS, 19 as a novel candidate PCa susceptibility gene. This study is the first report of coding PPFIBP2 mutations in PCa. We evaluated the association between pathogenic mutations in PPFIBP2 and lethal PCa in two large cohorts of lethal and low-risk PCa cases encompassing over 1400 subjects. The major novel finding of this study was that PPFIBP2 mutations were present at a significantly higher frequency in lethal PCa than in low-risk PCa cases.
The PPFIBP2 encoded protein is a beta liprin (known as Liprin-beta- phosphatases to the plasma membrane. 29 It is plausible that germline mutations in PPFIBP2 may down-regulate the expression levels of the encoded protein in PCa patients, contributing to more aggressive clinical behavior of the disease. PPFIBP2 has been reported as a potential biomarker for endometrial carcinoma. 30 In the TCGA, the median expression levels of PPFIBP2 were observed to be lower in PCa tumor tissues compared to normal tissues (P = 1.89 × 10
−10
). 19 In addition, a lower expression level of PPFIBP2 was associated with worse prognosis for prostate cancer at a preset threshold of lower than 10% in the data generated by Taylor In our study, a significantly higher mutation carrier frequency in PPFIBP2 was observed in European American lethal PCa patients than low-risk cases with a 14-fold increased risk of lethal PCa for patients who carried a PPFIBP2 mutation. However, the confidence interval OR and P-value were adjusted for first 2 eigens of genetic background.
FIGURE 2 Kaplan-Meier survival curves for PPFIBP2 mutation carriers and non-mutation carriers in the all European lethal prostate cancer cases (2.38-284.86) was wide due to the small number of carriers identified in the present study. This carrier frequency in our lethal cohort was also higher than both a clinically localized PCa cohort from TCGA (0%) and a general population from ExAC-NFE (0.17%). Moreover, the mutation carrier status proved to be an independent predictor of early death (P = 0.018) and short survival after adjusting for patients' age at diagnosis, PSA at diagnosis and genetic background (P = 0.034). Among the eight PPFIBP2 LOF mutation carriers, seven (88%) were lethal cases, and six of the seven lethal patients had either early-onset PCa (≤60 years at diagnosis) or short survival (≤5 years) after diagnosis (Supplementary Table S1 ). On the basis of the above evidence, we
propose that PPFIBP2 is a novel gene that may have utility in risk prediction for poor prognosis of PCa.
Several important limitations should be noted in this study. First and foremost, the number of PPFIBP2 carriers is small despite the large sample size, indicating the rareness of these mutations even within a lethal PCa cohort. Therefore, external validation studies in large populations are required before more supported assertions can be made. Secondly, while 101 African American patients were included in this study, the data were insufficient for statistical analysis of this ethnic cohort given the rarity of LOF mutations in PPFIBP2. Further studies of non-European cohorts would be necessary to determine prevalence and distribution of PPFIBP2 mutations across multi-ethnic populations, particularly since the cohort used in this study was primarily of European descent and PPFIBP2 LOF mutations were only detected in these patients.
| CONCLUSION
We provide evidence that germline mutations in PPFIBP2 may differentiate risk for lethal PCa from cases with low risk disease, as PPFIBP2 LOF mutations were associated with decreased survival following PCa diagnosis. If confirmed, loss of function mutations in PPFIBP2 could serve as novel germline predictors for poor prognosis of PCa.
